Telix Pharmaceuticals
Telix Pharmaceuticals is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) assets using Molecularly Targeted Radiation (MTR). The company annual revenue is 7 million AUD as on 2021. The headquarters is in Australia.